May 17 |
Fortress Biotech files for $50M mixed shelf
|
May 16 |
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
|
May 16 |
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
May 15 |
Fortress Biotech GAAP EPS of -$1.03 beats by $0.70, revenue of $13M misses by $1.13M
|
May 15 |
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
May 15 |
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
May 15 |
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
|
May 15 |
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
May 14 |
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
|
May 13 |
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|